<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Daudi Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells, unlike other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines, stimulate human T cells coexpressing the variable (V) region genes TCRG-V9 and V TCRD-V2 to proliferate and secrete lymphokines </plain></SENT>
<SENT sid="1" pm="."><plain>Hybrids, derived by the fusion of Daudi cells with the human <z:hpo ids='HP_0002861'>melanoma</z:hpo> cell line MZ2-MEL 2.2, retain the <z:mp ids='MP_0000002'>morphology</z:mp> of <z:hpo ids='HP_0002861'>melanoma</z:hpo> cells </plain></SENT>
<SENT sid="2" pm="."><plain>Unlike the parental <z:hpo ids='HP_0002861'>melanoma</z:hpo> cell line, these Daudi x MZ2-MEL 2.2 hybrids stimulate secretion of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) and granulocyte/macrophage colony stimulating factor (GM-CSF) by CD4-positive Vgamma9/Vdelta2 T-cell clones </plain></SENT>
<SENT sid="3" pm="."><plain>Whereas the stimulator phenotype of Daudi cells behaves as a dominant trait in Daudi x <z:hpo ids='HP_0002861'>melanoma</z:hpo> hybrids, the expression of B-cell differentiation markers is suppressed </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, the gamma/delta T-cell ligand expressed by Daudi cells behaves as a dominant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> antigen in Daudi x <z:hpo ids='HP_0002861'>melanoma</z:hpo> hybrids and is unrelated to the differentiated B-<z:mp ids='MP_0005384'>cell phenotype</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Dominant expression of the Daudi ligand for human Vgamma9/Vdelta2 T cells in these hybrids may provide a basis for defining the stimulatory principle at the molecular level </plain></SENT>
</text></document>